Danegaptide clinical trials
Also written GAP-134.
- studies test it
- 4
- open now
- 0
- in phase 3
- 0
- first study started
- 2007
How each study uses danegaptide is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
4 studies that test it; most in 2007 (2)
| Year | Studies |
|---|---|
| 2007 | 2 |
| 2008 | 1 |
| 2013 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 4 · Other 0
Wyeth is now a wholly owned subsidiary of Pfizer (3) · Zealand Pharma (1)
Studies
Open first, then newest update. How each study uses danegaptide is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 4
- Single Ascending Dose of GAP-134 as a 24-hour IV Infusion in Healthy Japanese MalesCompletedPhase 1Wyeth is now a wholly owned subsidiary of PfizerNCT00543946Written as GAP-134
- Phase 2 Clinical Proof-of-Concept Study of the Cardioprotective Properties of Danegaptide in ST Segment Elevation Myocardial InfarctionCompletedPhase 2Zealand PharmaNCT01977755Written as danegaptide
- Study of the Safety, Tolerability, and Pharmacokinetics of GAP-134 Administered IntravenouslyCompletedPhase 1Wyeth is now a wholly owned subsidiary of PfizerNCT00783341Written as GAP-134
- Single Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of GAP-134 Administered IntravenouslyCompletedPhase 1Wyeth is now a wholly owned subsidiary of PfizerNCT00510029Written as GAP-134
Codes
What other systems call danegaptide · ClinicalTrials.gg INT000694
- MeSH (NLM) C000619914danegaptideOne source NLM
- UNII (FDA) PA0Y7735ATDANEGAPTIDEConfirmed FDA, NLM, Wikidata
- Wikidata Q27286426danegaptideConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C83647DanegaptideOne source FDA
- DrugBank DB11821One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000619914 | danegaptide | One source NLM |
| UNII (FDA) | PA0Y7735AT | DANEGAPTIDE | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q27286426 | danegaptide | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C83647 | Danegaptide | One source FDA |
| DrugBank | DB11821 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.